Obtaining differentiated cells with high physiological functions by an efficient, but simple and rapid differentiation method is crucial for modeling neuronal diseases in vitro using human pluripotent stem cells (hPSCs). Currently, methods involving the transient expression of one or a couple of transcription factors have been established as techniques for inducing neuronal differentiation in a rapid, single step. It has also been reported that microRNAs can function as reprogramming effectors for directly reprogramming human dermal fibroblasts to neurons. In this study, we tested the effect of adding neuronal microRNAs, miRNA-9/9*, and miR-124 (miR-9/9*-124), for the neuronal induction method of hPSCs using Tet-On-driven expression of the Neurogenin2 gene (Ngn2), a proneural factor. While it has been established that Ngn2 can facilitate differentiation from pluripotent stem cells into neurons with high purity due to its neurogenic effect, a long or indefinite time is required for neuronal maturation with Ngn2 misexpression alone. With the present method, the cells maintained a high neuronal differentiation rate while exhibiting increased gene expression of neuronal maturation markers, spontaneous calcium oscillation, and high electrical activity with network bursts as assessed by a multipoint electrode system. Moreover, when applying this method to iPSCs from Alzheimer's disease (AD) patients with presenilin-1 (PS1) or presenilin-2 (PS2) mutations, cellular phenotypes such as increased amount of extracellular secretion of amyloid β42, abnormal oxygen consumption, and increased reactive oxygen species in the cells were observed in a shorter culture period than those previously reported. Therefore, it is strongly anticipated that the induction method combining Ngn2 and miR-9/9*-124 will enable more rapid and simple screening for various types of neuronal disease phenotypes and promote drug discovery.
Keywords: Alzheimer’s disease; excitatory neuron; human pluripotent stem cell; microRNA-124; microRNA-9/9*; neurogenin2; presenilin1; presenilin2.
Conflict of interest statement
H.O. is a scientific consultant for SanBio, Co. Ltd., and K Pharma Inc. The other authors declare neither financial nor non-financial competing interests.
Adipose-Derived Stem Cells Expressing the Neurogenin-2 Promote Functional Recovery After Spinal Cord Injury in Rat.Cell Mol Neurobiol. 2016 Jul;36(5):657-67. doi: 10.1007/s10571-015-0246-y. Epub 2015 Aug 18. Cell Mol Neurobiol. 2016. PMID: 26283493
Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons.Stem Cells Transl Med. 2019 Feb;8(2):112-123. doi: 10.1002/sctm.18-0036. Epub 2018 Nov 1. Stem Cells Transl Med. 2019. PMID: 30387318 Free PMC article.
Modeling familial Alzheimer's disease with induced pluripotent stem cells.Hum Mol Genet. 2011 Dec 1;20(23):4530-9. doi: 10.1093/hmg/ddr394. Epub 2011 Sep 7. Hum Mol Genet. 2011. PMID: 21900357
Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms.Prog Neurobiol. 2000 Mar;60(4):363-84. doi: 10.1016/s0301-0082(99)00033-7. Prog Neurobiol. 2000. PMID: 10670705 Review.
Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.Brain Res. 2016 May 1;1638(Pt A):30-41. doi: 10.1016/j.brainres.2015.09.023. Epub 2015 Sep 28. Brain Res. 2016. PMID: 26423934 Free PMC article. Review.
- Imaizumi K., Sone T., Ibata K., Fujimori K., Yuzaki M., Akamatsu W., Okano H. Controlling the Regional Identity of hPSC-Derived Neurons to Uncover Neuronal Subtype Specificity of Neurological Disease Phenotypes. Stem Cell Rep. 2015;5:1010–1022. doi: 10.1016/j.stemcr.2015.10.005. - DOI - PMC - PubMed
- 17bm0804014h0101/Japan Agency for Medical Research and Development
- 18bm0804014h0102/Japan Agency for Medical Research and Development
- 19bm0804014h0103/Japan Agency for Medical Research and Development
- 15bm0609003h0004/Japan Agency for Medical Research and Development
- 16bm0609003h0005/Japan Agency for Medical Research and Development
- 17bm0609003h0006/Japan Agency for Medical Research and Development
- 17bm0804003h0001/Japan Agency for Medical Research and Development
- 18bm0804003h0002/Japan Agency for Medical Research and Development
- 19bm0804003h0003/Japan Agency for Medical Research and Development
- 15bk0104027h003/Japan Agency for Medical Research and Development
- 16bk0104016h0004/Japan Agency for Medical Research and Development
- 17bk0104016h0005/Japan Agency for Medical Research and Development
- JP1710083/Japan Society for the Promotion of Science
- JP26830018/Japan Society for the Promotion of Science